AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 17720993
Drug: High dose
RxNorm normalized name: INFLUENZA VACCINE HIGH DOSE 0.5ML SYR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High dose Urocortin 2 (100 microg)
Trial: 16633764
Drug: Preoperative flurbiprofen
RxNorm normalized name: Flurbiprofen
DrugBank: Flurbiprofen (DB00712)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Preoperative flurbiprofen axetil, 1 mg x kg(‐1)
Trial: 14514944
Drug: Standard treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard treatment (ACBT)
Trial: 10789839
Drug: Tacalcitol 0.4
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tacalcitol 0.4 microg/g ointment
Trial: 10789839
Drug: Tacalcitol 4
RxNorm normalized name: Tacalcitol 4 microgram/g cutaneous ointment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tacalcitol 4 microg/g ointment
Trial: 10789839
Drug: Tacalcitol 40
RxNorm normalized name: tacalcitol
DrugBank: Tacalcitol (DB13689)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tacalcitol 40 microg/g ointment
Trial: 8695107
Drug: Intrathecal fentanyl
RxNorm normalized name: Fentanyl
DrugBank: Fentanyl (DB00813)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Intrathecal fentanyl 25 micrograms administered through a spinal needle
Trial: 8695107
Drug: No intravenous
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No intravenous (i.v.) fluid
Trial: 1832500
Drug: AM3 (a
FDA approved: no
EMA approved: no
PMDA approved: no
Description: AM3 (a new oral biological response modifier)
Trial: 1832500
Drug: Oral washes
RxNorm normalized name: Zencia Wash
DrugBank: Octasulfur (DB09353)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral washes (control group)
Trial: 6350411
Drug: Nifedipine (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nifedipine (10 mg single dose)
Trial: 6350411
Drug: Nifedipine (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nifedipine (10 mg t.i.d. for 4 days)
Trial: 6350411
Drug: Placebo treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo treatment (4 days)
Trial: 26681392
Drug: Ranibizumab or
RxNorm normalized name: Ranibizumab
DrugBank: Ranibizumab (DB01270)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Ranibizumab or Bevacizumab (anti-VEGF drugs)
Trial: 19160408
Drug: Two applications
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Two applications of Mitomycin-C (MMC) (0.5 mg/mL)
Trial: 19160408
Drug: One application
RxNorm normalized name: Gel-One
FDA approved: no
EMA approved: no
PMDA approved: no
Description: One application of Mitomycin-C (MMC) (0.5 mg/mL)
Trial: 16385651
Drug: Thiopental (2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Thiopental (2 mL, 50 mg)
Trial: 20581776
Drug: Saline (2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Saline (2 mL)
Trial: 10543285
Drug: SR 27417A
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SR 27417A (20 mg, orally)
Trial: 2182288
Drug: Mifepristone (longer
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mifepristone (longer treatment)
Trial: 7404090
Drug: Prolonged glucagon
RxNorm normalized name: Glucagon
DrugBank: Glucagon (DB00040)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Prolonged glucagon infusion
Trial: 27806191
Drug: 100 mg
RxNorm normalized name: urea 100 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 100 mg acebilustat
Trial: 27806191
Drug: Acebilustat (50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acebilustat (50 mg and 100 mg)
Trial: 24057341
Drug: Tirofiban maintenance
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tirofiban maintenance infusion for 24 hours
Trial: 24057341
Drug: Tirofiban maintenance
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tirofiban maintenance infusion for 48 hours
Trial: 21477940
Drug: Concurrent carboplatin/paclitaxel
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Concurrent carboplatin/paclitaxel with 74 Gy 3D-CRT
Trial: 21477940
Drug: Concurrent gemcitabine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Concurrent gemcitabine with 74 Gy 3D-CRT
Trial: 21477940
Drug: Treatment-related pulmonary
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treatment-related pulmonary toxicity
Trial: 19039248
Drug: Carboplatin AUC
RxNorm normalized name: Carboplatin
DrugBank: Carboplatin (DB00958)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Carboplatin AUC 5 plus PLD 30 mg/m(2) every 3 weeks for 6 cycles
Trial: 19039248
Drug: Carboplatin AUC
RxNorm normalized name: Carboplatin
DrugBank: Carboplatin (DB00958)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Carboplatin AUC 5 plus paclitaxel 175 mg/m(2) every 3 weeks for 6 cycles
Trial: 17460368
Drug: Metformin 500-750
RxNorm normalized name: metformin hydrochloride 750 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Metformin 500-750 mg/day
Trial: 9684138
Drug: Postoperative transarterial
RxNorm normalized name: povidone-iodine
DrugBank: Povidone-iodine (DB06812)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Postoperative transarterial infusion chemotherapy (PTIC)
Trial: 7889228
Drug: Crossover designs
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Crossover designs with three or more treatment periods
Trial: 7889228
Drug: Interposing sufficiently
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Interposing sufficiently long 'washout' periods between successive treatments
Trial: 18091334
Drug: Postoperative radiotherapy
RxNorm normalized name: sodium fluoride
DrugBank: Sodium fluoride (DB09325)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Postoperative radiotherapy plus carboplatin 100 mg/m intravenously once weekly during radiation (arm B)
Trial: 14533615
Drug: Ezetimibe alone
RxNorm normalized name: Ezetimibe
DrugBank: Ezetimibe (DB00973)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Ezetimibe alone or added to existing statin therapy
Trial: 14618039
Drug: Concomitant beta-blocker
RxNorm normalized name: Beta Carotene
DrugBank: Beta carotene (DB06755)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Concomitant beta-blocker use
Trial: 25665612
Drug: Xuebijing injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Xuebijing injection (50 mL added with 100 mL of 0.9% sodium chloride injection, twice a day for 5 days)
Trial: 22951334
Drug: Involuntary medication
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Involuntary medication as the first choice intervention
Trial: 22951334
Drug: Involuntary medication
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Involuntary medication
Trial: 9595926
Drug: SQA (quaternary
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SQA (quaternary ammonium antimicrobial compounds)
Trial: 9595926
Drug: CL (clindamycin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CL (clindamycin 2% intravaginal cream)
Trial: 23815103
Drug: BDP nasal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BDP nasal aerosol 320 µg/day
Trial: 23815103
Drug: BDP nasal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BDP nasal aerosol 80 µg and 160 µg
Trial: 21829138
Drug: rcp45 vaccine
RxNorm normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: rcp45 vaccine (2 intranasal doses administered 4 to 10 weeks apart)
Trial: 21829138
Drug: rcp45 vaccine
RxNorm normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: rcp45 vaccine (2nd dose)
Trial: 21829138
Drug: cp45 vaccine
RxNorm normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: cp45 vaccine (biologically derived)
Trial: 21829138
Drug: rcp45 vaccine
RxNorm normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: rcp45 vaccine
Trial: 19468225
Drug: Ivabradine 5,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ivabradine 5, 7.5, or 10 mg b.i.d. for 3 or 4 months
Trial: 14757687
Drug: Insulin at
RxNorm normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Insulin at 2.5 U/h
Trial: 9395153
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of cognitive-behaviour therapy with a serotonergic antidepressant (fluvoxamine)
Trial: 9395153
Drug: Non-responders at
RxNorm normalized name: rose bengal AT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Non-responders at post-treatment
Trial: 9395153
Drug: Severity of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Severity of symptoms, motivation for treatment, and dimensional score on the PDQ-R for cluster A personality disorder
Trial: 8187446
Drug: Oral gold
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral gold (6-9 mg auranofin by mouth daily)
Trial: 8187446
Drug: Injectable gold
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Injectable gold (Solganal, aurothioglucose, 50-100 mg, intramuscularly, 2 to 4 weeks)
Trial: 3025306
Drug: IgG and
RxNorm normalized name: cytarabine and daunorubicin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IgG and IgM antibody reactivity
Trial: 29145626
Drug: Tobacco Treatment
RxNorm normalized name: Tobacco
DrugBank: Tobacco leaf (DB10710)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tobacco Treatment Advocates (TTAs) intervention with multiple visits, motivational interviewing, cessation counseling, and navigation to cessation resources
Trial: 29145626
Drug: Tobacco Treatment
RxNorm normalized name: Tobacco
DrugBank: Tobacco leaf (DB10710)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tobacco Treatment Advocates (TTAs) intervention
Trial: 28158212
Drug: nCPAP therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: nCPAP therapy for more than four hours per night, for more than 70% of nights
Trial: 28158212
Drug: nCPAP therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: nCPAP therapy (entire group)
Trial: 21565487
Drug: Celecoxib 400mg
RxNorm normalized name: CELECOXIB 400MG CAP
DrugBank: Celecoxib (DB00482)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Celecoxib 400mg b.i.d. in addition to palliative chemotherapy
Trial: 21565487
Drug: Placebo in
RxNorm normalized name: placebo INTRAVEN VIAL (ML)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo in addition to palliative chemotherapy
Trial: 17975234
Drug: Control (normal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control (normal saline 2 mL i.v.)
Trial: 15916166
Drug: 400 mg/d
RxNorm normalized name: ribociclib succinate 400 mg/day (200 mg x 2) ORAL TABLET
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 400 mg/d vitamin E and 1000 mg/d vitamin C for 30 days
Trial: 9690396
Drug: Initial 100‐microg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Initial 100‐microg intravenous bolus followed by a continuous 25 microg/hr octreotide infusion (group I)
Trial: 9690396
Drug: Continuous 25
RxNorm normalized name: Ivy Dry Super Continuous Spray
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Continuous 25 microg/hr octreotide infusion without an initial bolus (group II)
Trial: 9690396
Drug: Continuous placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Continuous placebo infusion (group III)
Trial: 2478049
Drug: PCA with
RxNorm normalized name: lauryl PCA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PCA with morphine (1.8 mg, n = 16)
Trial: 2478049
Drug: PCA with
RxNorm normalized name: lauryl PCA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PCA with oxymorphone (0.3 mg, n = 16)
Trial: 2478049
Drug: PCA +
RxNorm normalized name: lauryl PCA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PCA + BI with morphine (0.6 mg/hour, n = 16)
Trial: 2478049
Drug: PCA +
RxNorm normalized name: lauryl PCA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PCA + BI with oxymorphone (0.1 mg/hour, n = 16)
Trial: 29493100
Drug: Mitiglinide 10
RxNorm normalized name: mitiglinide
DrugBank: Mitiglinide (DB01252)
FDA approved: no
EMA approved: no
PMDA approved: yes
Description: Mitiglinide 10 mg/voglibose 0.2 mg three times daily for 3 days
Trial: 29493100
Drug: Glimepiride 1
RxNorm normalized name: glimepiride 1 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Glimepiride 1 mg once daily for 3 days
Trial: 27607411
Drug: Combination therapy
RxNorm normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination therapy (methotrexate+sulfasalazine+hydroxychloroquine with prednisolone)
Trial: 27607411
Drug: Combination therapy
RxNorm normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination therapy with anti-TNF induction (infliximab)
Trial: 27607411
Drug: Combination therapy
RxNorm normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination therapy with placebo
Trial: 23282652
Drug: Sublingual immunotherapy
RxNorm normalized name: Adoptive immunotherapy agent CTL019
DrugBank: Tisagenlecleucel (DB13881)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sublingual immunotherapy (SLIT) for allergic rhinitis
Trial: 23282652
Drug: Sublingual immunotherapy
RxNorm normalized name: Adoptive immunotherapy agent CTL019
DrugBank: Tisagenlecleucel (DB13881)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sublingual immunotherapy (SLIT) for asthma associated with rhinitis
Trial: 23282652
Drug: Sublingual immunotherapy
RxNorm normalized name: Adoptive immunotherapy agent CTL019
DrugBank: Tisagenlecleucel (DB13881)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sublingual immunotherapy (SLIT) for atopic dermatitis, latex allergy, and hymenoptera hypersensitivity
Trial: 12719883
Drug: Saline +
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Saline + furosemide (40 mg after hydration)
Trial: 12719883
Drug: Saline +
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Saline + mannitol (50 g mixed with cisplatin)
Trial: 8859177
Drug: Indomethacin suppository
RxNorm normalized name: indomethacin Rectal Suppository
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Indomethacin suppository (50 mg) administered once or twice daily for 4 or 8 weeks
Trial: 8859177
Drug: Indomethacin suppository
RxNorm normalized name: indomethacin Rectal Suppository
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Indomethacin suppository (50 mg)
Trial: 1536727
Drug: Cyclosporin 6
RxNorm normalized name: Cyclosporine
DrugBank: Cyclosporine (DB00091)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cyclosporin 6 mg/kg body wt. per day for 3 months and tapering doses over the next 3 months
Trial: 1536727
Drug: Chlorambucil at
RxNorm normalized name: Chlorambucil
DrugBank: Chlorambucil (DB00291)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Chlorambucil at a cumulative dose of 8 mg/kg body wt.
Trial: 6097125
Drug: Cefmenoxime (0.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cefmenoxime (0.5 to 1 g every six hours)
Trial: 6097125
Drug: Cefoxitin (1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cefoxitin (1 to 2 g every six hours)
Trial: 25461792
Drug: Wait-list condition
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Wait-list condition (W-L)
Trial: 17704023
Drug: n‐3 PUFA/gamma‐CD
FDA approved: no
EMA approved: no
PMDA approved: no
Description: n‐3 PUFA/gamma‐CD complex (660 mg EPA + 280 mg DHA/day)
Trial: 17704023
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (capsules containing essentially no n‐3 PUFA)
Trial: 12045164
Drug: Aspirin 1.2
RxNorm normalized name: Aspirin 1.2 GM Rectal Suppository
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aspirin 1.2 g orally 2 hours before vaccination
Trial: 12045164
Drug: Local intrabrachial
RxNorm normalized name: docusate calcium / phenolphthalein Oral Capsule [Docal]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Local intrabrachial aspirin 10 mg/min for 15 minutes
Trial: 2021561
Drug: Intensive treatment
RxNorm normalized name: Head & Shoulders Intensive Treatment
DrugBank: Selenium Sulfide (DB00971)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intensive treatment (test group, N=17)
Trial: 29663291
Drug: Apatinib (oral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Apatinib (oral administration)
Trial: 12706704
Drug: Trivalent live,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Trivalent live, cold‐adapted influenza virus vaccine (CAIV‐T) co-administered with trivalent inactivated influenza virus vaccine (TVV)
Trial: 12706704
Drug: Trivalent inactivated
RxNorm normalized name: diphtheria toxoid vaccine, inactivated / tetanus toxoid vaccine, inactivated Injection [Tdvax]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Trivalent inactivated influenza virus vaccine (TVV) and placebo (TP)
Trial: 1318765
Drug: Hepatitis A
RxNorm normalized name: HEPATITIS A
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hepatitis A vaccine (group 1, 54 volunteers) at 0, 1, and 2 months
Trial: 1318765
Drug: Hepatitis A
RxNorm normalized name: HEPATITIS A
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hepatitis A vaccine (group 2, 50 volunteers) at 0, 1, and 6 months
Trial: 29514524
Drug: Onion extract
RxNorm normalized name: Onion Extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Onion extract gel
Trial: 24964176
Drug: Rivaroxaban 10
RxNorm normalized name: rivaroxaban 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rivaroxaban 10 mg co-administered with steady-state erythromycin in subjects with mild or moderate RI
Trial: 24964176
Drug: Rivaroxaban 10
RxNorm normalized name: rivaroxaban 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rivaroxaban 10 mg co-administered with steady-state erythromycin in subjects with moderate RI
Trial: 24964176
Drug: Rivaroxaban administered
RxNorm normalized name: Rivaroxaban
DrugBank: Rivaroxaban (DB06228)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Rivaroxaban administered alone in RI subjects
Trial: 24964176
Drug: Rivaroxaban co-administered
RxNorm normalized name: Rivaroxaban
DrugBank: Rivaroxaban (DB06228)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Rivaroxaban co-administered with steady-state erythromycin in NRF subjects
Trial: 20198713
Drug: Pardoprunox (9‐45
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pardoprunox (9‐45 mg/d, mean dose 23.8 mg/d)
Trial: 18302208
Drug: Pharmacotherapy with
RxNorm normalized name: Primatene with ephedrine Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pharmacotherapy with clinical management (PHT-CM)
Trial: 18427286
Drug: Epsilon-aminocaproic acid
RxNorm normalized name: Epsilon-Aminocaproic acid
DrugBank: Aminocaproic acid (DB00513)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Epsilon-aminocaproic acid (EACA) 5 g IV
Trial: 15307936
Drug: Thyroid hormone
RxNorm normalized name: Thyroid hormone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Thyroid hormone replacement therapy (levothyroxine)
Trial: 3307366
Drug: Digoxin plus
RxNorm normalized name: Digoxin
DrugBank: Digoxin (DB00390)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Digoxin plus nadolol (titrated from 20 to 120 mg daily)
Trial: 30661836
Drug: HydroVax-001 (1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HydroVax-001 (1 mcg dose)
Trial: 30661836
Drug: HydroVax-001 (4
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HydroVax-001 (4 mcg dose)
Trial: 27092472
Drug: Endovascular therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Endovascular therapy plus intravenous tPA administration
Trial: 22350679
Drug: 100 mcg
RxNorm normalized name: Levo-T 100 MCG Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 100 mcg of HFA‐BDP twice daily
Trial: 22350679
Drug: 400 mcg
RxNorm normalized name: Biotin 400 MCG Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 400 mcg of HFA‐BDP twice daily
Trial: 22350679
Drug: Oral prednisolone
RxNorm normalized name: prednisolone Oral Solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral prednisolone (25 mg/day)
Trial: 20212073
Drug: High-dose niacin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose niacin 2000 mg plus lovastatin 40 mg
Trial: 20212073
Drug: Low-dose niacin
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose niacin 1000 mg plus lovastatin 40 mg
Trial: 16375657
Drug: Ginkgo biloba
RxNorm normalized name: Ginkgo Biloba
DrugBank: Ginkgo biloba (DB01381)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ginkgo biloba extract (GbE) at daily doses of 120 mg
Trial: 16375657
Drug: Ginkgo biloba
RxNorm normalized name: Ginkgo Biloba
DrugBank: Ginkgo biloba (DB01381)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ginkgo biloba extract (GbE) at daily doses of 240 mg
Trial: 1102484
Drug: Ara‐A ointment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ara‐A ointment
Trial: 1102484
Drug: IDU ointment
RxNorm normalized name: IdU
DrugBank: Idoxuridine (DB00249)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: IDU ointment
Trial: 31174526
Drug: Ticagrelor 90
RxNorm normalized name: ticagrelor 90 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ticagrelor 90 mg twice daily with aspirin 81 mg
Trial: 31174526
Drug: Ticagrelor 90
RxNorm normalized name: ticagrelor 90 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ticagrelor 90 mg twice daily without aspirin
Trial: 21550027
Drug: Amolimogene (microparticle
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Amolimogene (microparticle encapsulated pDNA vaccine)
Trial: 19301724
Drug: Continuous epidural
RxNorm normalized name: ACCU-BLOC PERIFIX CONTINUOUS EPIDURAL ANESTHESIA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Continuous epidural infusion (CEI) with 0.125% levobupivacaine and morphine 0.0125 mg/ml (4 ml/hr)
Trial: 19301724
Drug: Continuous femoral
RxNorm normalized name: Ivy Dry Super Continuous Spray
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Continuous femoral nerve block (CFNB) with 0.125% levobupivacaine (8 ml/hr)